Biopharma CEOs Talk Public Image and Pricing

With criticisms and praises levied at the industry from all sides, biotech companies occupy a precarious place in the public discourse. Leaders in biopharma have to account for this to achieve success moving forward. In a recent Life Science Leader article, three biopharma CEOs were asked about the relationship between the public and their industry.

According to Andrea Pfiefer, CEO, AC Immune, “Pricing is a political issue that clouds the real issue — the overall price of healthcare. For COVID-19, many stakeholders united to accelerate development of an effective vaccine much faster than anyone could have imagined. Effective therapies save money, preserve quality of life, and make economic sense. Otherwise, we are not delivering on our promise — and who wants to pay for that?”

To read more, click here.

(Source: Life Science Leader, December 1^st, 2022)